MARKET

ALRN

ALRN

Aileron Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2600
-0.0402
-13.39%
After Hours: 0.2698 +0.0098 +3.77% 18:26 06/30 EDT
OPEN
0.3050
PREV CLOSE
0.3002
HIGH
0.3050
LOW
0.2525
VOLUME
1.06M
TURNOVER
0
52 WEEK HIGH
1.340
52 WEEK LOW
0.2525
MARKET CAP
23.61M
P/E (TTM)
-0.8530
1D
5D
1M
3M
1Y
5Y
--HC Wainwright Adjusts Price Target on Aileron Therapeutics to $1 From $2, Reiterates Buy Rating
MT Newswires · 1d ago
Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting
Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without imm...
Benzinga · 1d ago
Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trial
Aileron Therapeutics (NASDAQ:ALRN) <a href="https://seekinga...
Seekingalpha · 1d ago
BRIEF-Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer
BRIEF-Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer
Reuters · 2d ago
Aileron Therapeutics Announced Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced interim data from its Phase 1b chemoprotection trial of patients with ...
Benzinga · 2d ago
--Ladenburg Thalmann Initiates Coverage on Aileron Therapeutics With Buy Rating, $2 Price Target
MT Newswires · 06/13 09:28
BRIEF-Aileron Therapeutics Files For Mixed Shelf Of Up To $150 Million
reuters.com · 06/08 10:22
BRIEF-Aileron Therapeutics Says Board Appointed Manuel Aivado, Co's CEO To Serve As Co's Principal Financial Officer, Principal Accounting Officer
reuters.com · 06/07 12:43
More
No Data
Learn about the latest financial forecast of ALRN. Analyze the recent business situations of Aileron Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
25.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALRN stock price target is 1.500 with a high estimate of 2.000 and a low estimate of 1.000.
High2.000
Average1.500
Low1.000
Current 0.2600
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 38.66M
% Owned: 42.57%
Shares Outstanding: 90.82M
TypeInstitutionsShares
Increased
6
159.75K
New
7
286.90K
Decreased
13
1.65M
Sold Out
7
111.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.17%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Bailey
President/Chief Executive Officer/Director
Manuel Alves Aivado
Chief Financial Officer
Susan Drexler
Senior Vice President
D. Allen Annis
Senior Vice President
Vojislav Vukovic
Vice President
Christopher Zergebel
Independent Director
Reinhard Ambros
Independent Director
William Mckee
Independent Director
Jodie Morrison
Independent Director
Nolan Sigal
Independent Director
Josef Von Rickenbach
No Data
No Data
About ALRN
Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALRN stock methods without spending real money on the virtual paper trading platform.